Russia’s consumer health watchdog Rospotrebnadzor on Tuesday said Russia’s second vaccine against COVID-19 is 100% effective based on the results of clinical trials, the TASS news agency reported. Russia began mass trials of EpiVacCorona, which is being developed by Siberia’s Vector Institute, in November. Moscow has said its other approved COVID-19 vaccine, Sputnik V, is 92%
Russia says its second Covid vaccine is 100% effective post clinical trials: Report
Premium
Loana Poza, 37, gets vaccinated with the Sputnik V (Gam-COVID-Vac) vaccine at the San Martin hospital, in La Plata, on the outskirts of Buenos Aires, Argentina January 18, 2021. REUTERS/Agustin Marcarian
(REUTERS)
Mass production of the country s second Covid vaccine, will be launched in February 2021
Share Via
Read Full Story
Russia on Tuesday said that its second Covid-19 vaccine manufactured by Vector Institute has shown 100% efficacy. The announcement is based on results of clinical trials, reported Reuters quoting news agency TASS.
Russia began mass trials of EpiVacCorona, which is being developed by Siberia s Vector Institute, in November.
By Reuters Staff
1 Min Read
MOSCOW, Jan 19 (Reuters) - Russia’s consumer health watchdog Rospotrebnadzor on Tuesday said Russia’s second vaccine against COVID-19 is 100% effective based on the results of clinical trials, the TASS news agency reported.
Russia began mass trials of EpiVacCorona, which is being developed by Siberia’s Vector Institute, in November.
Moscow has said its other approved COVID-19 vaccine, Sputnik V, is 92% effective at protecting people from COVID-19 according to interim results. (Reporting by Maria Kiselyova; Writing by Alexander Marrow; Editing by Louise Heavens)
A candidate COVID-19 vaccine known as EpiVacCorona, Russia's second to be registered, proved "100% effective" in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media.